These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8965474)

  • 1. [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis].
    Spraul CW; Schicketanz C; Lang GE
    Klin Monbl Augenheilkd; 1996 Jul; 209(1):31-6. PubMed ID: 8965474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
    Baath JS; Lam WC; Kirby M; Chun A
    Retina; 2008 Jun; 28(6):894-9. PubMed ID: 18536609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
    Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ocular toxicity of deferoxamine: description and analysis of three observations].
    Szwarcberg J; Mack G; Flament J
    J Fr Ophtalmol; 2002 Jun; 25(6):609-14. PubMed ID: 12223949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retinal pigment epithelium--desferal].
    Roulez F
    Bull Soc Belge Ophtalmol; 2007; (304):59-66. PubMed ID: 17718228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy.
    Tyni T; Kivelä T; Lappi M; Summanen P; Nikoskelainen E; Pihko H
    Ophthalmology; 1998 May; 105(5):810-24. PubMed ID: 9593380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ocular findings in Desferal therapy].
    Dennerlein JA; Lang GE; Stahnke K; Kleihauer E; Lang GK
    Ophthalmologe; 1995 Feb; 92(1):38-42. PubMed ID: 7719074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desferrioxamine related maculopathy: a case report.
    Arora A; Wren S; Gregory Evans K
    Am J Hematol; 2004 Aug; 76(4):386-8. PubMed ID: 15282675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
    Olivieri NF; Buncic JR; Chew E; Gallant T; Harrison RV; Keenan N; Logan W; Mitchell D; Ricci G; Skarf B
    N Engl J Med; 1986 Apr; 314(14):869-73. PubMed ID: 3485251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bull's-Eye Maculopathy with Deferoxamine Treatment].
    Schmidt D; Finke J
    Klin Monbl Augenheilkd; 2004 Mar; 221(3):204-9. PubMed ID: 15052528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ocular safety: tirapazamine plus cisplatin in patients with metastatic melanomas.
    Prager TC; Kellaway J; Zou Y; Urso RG; McIntyre S; Bedikian AY
    Anticancer Drugs; 1998 Jul; 9(6):515-24. PubMed ID: 9877239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
    Kobayashi M; Yano K; Fujisawa S
    Rinsho Ketsueki; 1996 Apr; 37(4):303-10. PubMed ID: 8847800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium iodate toxic retinopathy: a report of five cases.
    Singalavanija A; Ruangvaravate N; Dulayajinda D
    Retina; 2000; 20(4):378-83. PubMed ID: 10950416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy.
    Lakhanpal V; Schocket SS; Jiji R
    Ophthalmology; 1984 May; 91(5):443-51. PubMed ID: 6739047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases.
    Van Bol L; Alami A; Benghiat FS; Rasquin F
    Retin Cases Brief Rep; 2014; 8(2):97-102. PubMed ID: 25372319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and therapeutic challenges.
    Reddy S; Slakter J; Aaberg TM; Singh RP; Kaiser PK
    Retina; 2007 Jun; 27(5):642-7. PubMed ID: 17558329
    [No Abstract]   [Full Text] [Related]  

  • 18. [First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis].
    Giraud P; Orsini A; Giraud F; Pinsard N
    Arch Fr Pediatr; 1965 Apr; 22(4):463-8. PubMed ID: 5826583
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diffuse retinal pigmented epitheliopathy associated with systemic corticosteroid therapy].
    Spraul CW; Jakobczyk-Zmija MJ; Lang GK; Lang GE
    Klin Monbl Augenheilkd; 2000 Jun; 216(6):424-7. PubMed ID: 10919123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optic neuritis with visual field defect--possible Ibuprofen-related toxicity.
    Gamulescu MA; Schalke B; Schuierer G; Gabel VP
    Ann Pharmacother; 2006 Mar; 40(3):571-3. PubMed ID: 16507621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.